Regeneron(REGN) Globenewswire·2025-06-15 15:21Core Insights - Dupixent demonstrated superior efficacy compared to Xolair in treating chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma, achieving significant improvements in various endpoints as early as 4 weeks [1][2][3] Group 1: Trial Overview - The EVEREST Phase 4 trial involved 360 adults with severe, uncontrolled CRSwNP and coexisting asthma, comparing Dupixent (300 mg every two weeks) to Xolair (dosing based on weight and IgE levels) [2][5] - Both treatments were administered alongside mometasone furoate nasal spray [2][5] Group 2: Efficacy Results - Dupixent achieved a 1.60-point superior reduction in nasal polyp size (p<0.0001) and an 8.0-point superior improvement in smell identification (p<0.0001) [4] - Other notable results included a 0.58-point reduction in nasal congestion (p<0.0001), a 1.74-point reduction in symptom severity (p<0.0001), and a 12.7-point improvement in health-related quality of life (p<0.0001) [4] Group 3: Safety Profile - The safety profile of Dupixent was consistent with its known profile, with adverse event rates of 64% for Dupixent and 67% for Xolair [3] - Serious adverse events were reported in 2% of Dupixent patients compared to 4% for Xolair, and discontinuation due to adverse events occurred in 3% of Dupixent patients versus 1% for Xolair [3] Group 4: Mechanism of Action - Dupixent targets IL-4 and IL-13 pathways, which are key drivers of type 2 inflammation, providing significant clinical benefits in respiratory diseases [1][7] Group 5: Market Context - Dupixent has received regulatory approvals in over 60 countries for various indications, with more than 1,000,000 patients currently treated globally [8][9]